The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials

Abstract Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent. Explanations for the negative results of therapeutic trials include a likely heterogeneity, both in disease susceptibility and pathogenic mechanisms, and faulty methodology of clinical trials. Further understanding of these factors will lead to improvements in patient stratification, and in the design of future clinical trials.

[1]  D. Deforge,et al.  Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. , 2012, The Cochrane database of systematic reviews.

[2]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[3]  Matthew C Kiernan,et al.  Biomarkers in amyotrophic lateral sclerosis , 2009, The Lancet Neurology.

[4]  E. Beghi,et al.  Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[5]  W. Bamlet,et al.  Subcutaneous IGF-1 is not beneficial in 2-year ALS trial , 2008, Neurology.

[6]  E. Beghi,et al.  Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[7]  Adriano Chiò,et al.  The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. , 2007, Current medicinal chemistry.

[8]  W. Burke.  Neuroprotective agents for clinical trials in ALS: A systematic assessment , 2007, Neurology.

[9]  R. Orrell,et al.  Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease. , 2007, The Cochrane database of systematic reviews.

[10]  E. Beghi,et al.  Incidence of ALS in Lombardy, Italy , 2007, Neurology.

[11]  John L.P. Thompson,et al.  Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trial , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[12]  E. Beghi,et al.  The epidemiology of ALS and the role of population-based registries. , 2006, Biochimica et biophysica acta.

[13]  C. Shaw,et al.  Amyotrophic Lateral Sclerosis/Motor Neuron Disease , 2006 .

[14]  R. Olney,et al.  Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. , 2006, The Cochrane database of systematic reviews.

[15]  A. Chiò,et al.  Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  E. Beghi.  127th ENMC International Workshop: Implementation of a European Registry of ALS Naarden, The Netherlands, 8–10 October 2004 1 , 2006, Neuromuscular Disorders.

[17]  E. Beghi,et al.  Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  S. Grambow,et al.  Estimating the Occurrence of Amyotrophic Lateral Sclerosis among Gulf War (1990–1991) Veterans Using Capture-Recapture Methods , 2005, Neuroepidemiology.

[19]  P. Bongioanni,et al.  Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. , 2004, The Cochrane database of systematic reviews.

[20]  Miller Rg,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) , 2003 .

[21]  O. Hardiman,et al.  Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000 , 2003, Journal of neurology, neurosurgery, and psychiatry.

[22]  J. Murphy,et al.  Can we eliminate placebo in ALS clinical trials? , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[23]  G. Borasio,et al.  Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. , 2002, The Cochrane database of systematic reviews.

[24]  Incidence of ALS in Italy: Evidence for a uniform frequency in Western countries , 2001 .

[25]  M. Druet‐Cabanac,et al.  Estimation of the amyotrophic lateral sclerosis incidence by capture-recapture method in the Limousin region of France. , 2000, Journal of clinical epidemiology.

[26]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[27]  O. Hardiman,et al.  Incidence and prevalence of ALS in Ireland, 1995–1997 , 1999, Neurology.

[28]  T. Koepsell,et al.  Incidence of amyotrophic lateral sclerosis in three counties in western Washington state , 1996, Neurology.

[29]  C. Warlow,et al.  Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[30]  P. Andres,et al.  The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials , 1993, Neurology.

[31]  J. Annegers,et al.  Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. , 1991, Archives of neurology.

[32]  G. Smith,et al.  A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience , 1987, Annals of neurology.

[33]  Richard W. Bohannon,et al.  Interrater reliability of a modified Ashworth scale of muscle spasticity. , 1987, Physical therapy.

[34]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[35]  F. Norris,et al.  The administration of guanidine in amyotrophic lateral sclerosis , 1974, Neurology.

[36]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[37]  R. Orrell,et al.  Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease. , 2007, The Cochrane database of systematic reviews.

[38]  W. Burke.  Neuroprotective agents for clinical trials in ALS: systematic assessment. , 2006, Neurology.

[39]  O. Hardiman,et al.  Amyotrophic lateral sclerosis mimic syndromes: a population-based study. , 2000, Archives of neurology.

[40]  R R Regal,et al.  Capture-recapture methods in epidemiology: methods and limitations. , 1995, Epidemiologic reviews.

[41]  A. Berardelli,et al.  Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? , 1993 .